Acorda’s Preclinical programs are exploring several therapeutic approaches that may restore and/or regenerate portions of the central nervous system (CNS).

Recent scientific data indicate that modification of the inhibitory scar matrix potentially can permit nerve regeneration and functional recovery to occur. We have developed a program based on the concept of breaking down the matrix of scar tissue that develops as a result of an injury to the CNS.

The Company’s remyelination program includes two technologies to address the loss or damage of myelin on axons that have been injured either by trauma (such as a spinal cord injury) or by disease (such as multiple sclerosis). Myelin is the insulating layer of cells that surround nerve fibers.